Keyora Antarctic Krill Oil EP-15: The Osteoarthritis Phenotype-Matching and Response Algorithm: Phospholipid Omega-3 Across Inflammatory Resolution, Pain, Stiffness, Function, and the Structural Disease-Modification Boundary

Background Osteoarthritis is commonly described as a degenerative disorder caused by progressive “wear and tear” of articular cartilage. This description captures the importance of cumulative mechanical loading but fails to represent the biological, structural, nociceptive, and functional complexity of the disease. Contemporary osteoarthritis biology supports a whole-joint model. Articular cartilage degeneration occurs within a system that also includes subchondral bone remodeling, synovial activity, periarticular tissues, muscle function, biomechanical loading, osteochondral crosstalk, nociceptive signaling, pain sensitization, and functional adaptation. These components interact over time, but they do not change in parallel. A patient may experience substantial pain despite relatively limited radiographic disease. Another may have extensive structural abnormalities with more modest pain. Synovitis may coexist with cartilage degeneration without becoming the dominant biological feature in every patient. Physical function can improve despite persistence of structural disease. Similarly, short-term symptom relief cannot be promoted into evidence of cartilage repair or long-term disease modification. Keyora Antarctic Krill Oil EP-15 therefore develops Keyora [The Joint Resolution-Structure-Function Matrix] to organize osteoarthritis into three interacting but non-equivalent domains: Resolution Structure and: Function. The Resolution Layer concerns local inflammatory activity, synovial biology, membrane-derived lipid mediators, and the biological processes involved in termination of inflammation and restoration of tissue homeostasis. The Structure Layer concerns articular cartilage, subchondral bone, osteophytes, joint-space change, osteochondral remodeling, and whole-joint progression. The Function Layer concerns pain, stiffness, mobility, walking, stair use, physical activity, exercise capacity, and participation in valued daily activities. The controlling evidence principle is: Resolution response ≠ structural modification ≠ symptom improvement ≠ functional recovery. Within this architecture, Keyora Antarctic Krill Oil is positioned as a Phospholipid Omega-3 intervention at the inflammatory-resolution and symptom-function interface. EPA and DHA provide the principal resolution-related fatty-acid substrate context. DPA remains a visible secondary long-chain n-3 component with mechanistic relevance to resolution biology while carrying a more limited direct OA evidence base. Phospholipid form, phosphatidylcholine, and Choline contribute intervention identity and nutritional context, but the clinically decisive question is whether a defined Krill-Oil exposure produces a reproducible change in a prespecified OA response object. The article integrates positive and null direct human Krill-Oil randomized evidence and concludes with Keyora [The Osteoarthritis Phenotype-Matching and Response Algorithm], in which OA classification, dominant phenotype, response-object selection, exposure reconstruction, evidence transfer, same-endpoint reassessment, and clinical escalation are linked within one decision system. Objective The objectives of EP-15 are to: replace a cartilage-only wear-and-tear model of osteoarthritis with a whole-joint structure-inflammation-function framework; preserve cartilage degeneration as a central structural feature without treating cartilage as the complete disease; integrate articular cartilage, synovium, subchondral bone, periarticular tissues, muscle, and mechanical load into one whole-joint disease architecture; establish why structural severity, pain severity, inflammatory activity, and functional impairment do not necessarily progress in parallel; define pain, stiffness, physical function, mobility, activity loss, and imaging findings as separate clinical or structural response objects; establish Keyora [The Joint Resolution-Structure-Function Matrix]; distinguish the Resolution Layer from the Structure and Function Layers; establish the mechanical, structural, and inflammatory crosstalk through which cartilage stress, damage-associated signaling, synovial activation, and subchondral remodeling interact; preserve mechanical load as a primary OA driver even when inflammatory biology is clinically relevant; distinguish pain burden from structural disease burden; establish why articular cartilage itself cannot explain pain intensity because normal cartilage is aneural; integrate synovial, subchondral, capsular, ligamentous, muscular, and other periarticular nociceptive sources; integrate peripheral sensitization and central amplification as modifiers of OA pain without replacing joint pathology; define the clinical boundary established by exercise, weight management, self-management, pharmacological care, procedures, and specialist management; prevent biological plausibility for nutritional lipid intervention from displacing mechanical or evidence-based clinical care; define synovitis as a genuine but heterogeneous OA phenotype; distinguish synovial activation, effusion, effusion-synovitis, pain, and structural burden; establish that imaging-visible inflammatory abnormalities do not automatically identify a nutritional responder; integrate matrix-derived damage-associated molecular signaling and cartilage-synovium crosstalk into the inflammatory-resolution phenotype; distinguish active resolution of inflammation from simple suppression of pro-inflammatory signaling; establish the membrane-fatty-acid substrate context of inflammatory and resolution-related lipid mediators; position EPA within E-series resolution-related substrate biology without converting that mechanism into a guaranteed OA outcome; position DHA within D-series resolvin, protectin, and maresin-related substrate biology without converting substrate availability into guaranteed mediator production or clinical response; retain n-3 DPA as a secondary resolution-related substrate without promoting it into the primary OA intervention object; establish Phospholipid Omega-3 Resolution Interface as the controlling Keyora intervention concept within the Resolution Layer; define mechanical-structural, inflammatory-synovial, and mixed OA phenotypes; establish why biological phenotype fit does not equal clinical responder identification; establish Keyora [The Joint Response Object Map]; distinguish WOMAC pain from VAS and NRS pain; distinguish pain from stiffness; distinguish pain and stiffness from physical function; distinguish questionnaire function from broader mobility and activity; interpret rescue-medication use as contextual evidence rather than a substitute for primary clinical outcomes; evaluate direct positive human Krill-Oil evidence from the Stonehouse randomized trial; evaluate direct null human Krill-Oil evidence from the KARAOKE randomized trial; reconcile positive WOMAC and null VAS findings without converting either study into a universal verdict on Krill Oil; distinguish Omega-3 Index response from osteoarthritis efficacy; integrate baseline habitual long-chain Omega-3 exposure into evidence-transfer interpretation without claiming a validated OA responder threshold; distinguish Krill-Oil product grams from actual EPA/DHA exposure; establish why 4 g/day and 2 g/day Krill-Oil studies are different trial contexts rather than validated universal dose categories; reconstruct exact one- and two-softgel Keyora Phospholipid Omega-3 exposure; prohibit numerical exposure similarity from becoming exact-product efficacy equivalence; establish Keyora [The Joint Symptom-Structure Separation Rule]; establish that symptom relief cannot demonstrate cartilage regeneration; establish that functional improvement cannot demonstrate slower cartilage loss; establish that imaging-defined inflammatory change cannot substitute for direct structural progression outcomes; define radiographic joint-space width, cartilage morphology, and longitudinal MRI or radiographic endpoints as structural response objects; define the evidence requirements for disease-modification claims; explicitly exclude current claims of cartilage regrowth, reversal of joint-space narrowing, DMOAD-level efficacy, and proven long-term surgery prevention from Krill-Oil evidence; establish Keyora [The Joint Phenotype-Dose-Endpoint Matching Rule]; establish Keyora [The OA Reclassification and Escalation Gate]; operationalize the entire article through Keyora [The Osteoarthritis Phenotype-Matching and Response Algorithm]. Osteoarthritis as a Whole-Joint Disorder The biological starting point of EP-15 is that osteoarthritis is not an isolated cartilage lesion. Articular cartilage provides a load-bearing, low-friction surface, and cartilage-matrix deterioration remains a defining feature of OA. However, cartilage exists within a mechanically and biologically connected joint system. The broader whole-joint architecture includes: articular cartilage; subchondral bone; synovium; periarticular tissues; muscle; ligaments; capsule; meniscal or fibrocartilaginous structures where relevant; mechanical loading; sensory pathways; functional adaptation. These tissues interact rather than fail independently. Mechanical Loading Is Fundamental but Not Passive Abrasion Mechanical exposure remains central to OA pathogenesis. Abnormal or excessive load related to alignment, body mass, injury, instability, repetitive demand, or altered gait can increase tissue stress. However, living tissues respond actively to that stress. Mechanical loading can modify: extracellular-matrix integrity; chondrocyte signaling; subchondral remodeling; synovial biology; nociceptive activity; movement strateg